MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.21
+1.31%Margins
Gross margin
95.3%
EBITDA margin
-651.4%
EBIT margin
-728.1%
Net margin
-668.0%
FCF margin
-534.2%
-29.5%
Return on equity
-25.1%
Return on assets
-28.4%
Return on invested capital
0.04x
Asset turnover
-$106.5M
Cash from operations
$7.40
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026